Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
North America is occupying the largest regional market share in the global hemophilia A and B recombinant factor replacement therapy market owing to the presence of more number of market players, high awareness levels regarding the use of technologically advanced products for treatment of hemophilia. Healthcare expenditure and relatively larger number of R&D exercises pertaining to product manufacturing and commercialization is anticipated to drive the revenue growth of recombinant factor replacement therapy market in the region. Also Europe is expected to perform well in the near future due to increasing usage of technologically advanced devices for treatment of disorders such as hemophilia.
Asia Pacific is expected to grow at the fastest CAGR because of increasing prevalence of hemophilia in the region thus boosting the market growth of hemophilia A and B recombinant factor replacement therapy market throughout the forecast period.
Some players of hemophilia A and B recombinant factor replacement therapy market includes Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Uniqure. The companies in hemophilia A and B recombinant factor replacement therapy market are increasingly engaged in strategic partnerships, collaborations and marketing activities to capture a greater pie of market share as the market is in the nascent stage.